Just wondering if it is in big pharmas best interest to know earlier that a patient is developing DKD. If it means shorter treatment time using their drug, they might prefer their patients develop full blown DKD. Thinking that the money may come from GPs - where patients at risk of developing DVD (overweight etc.) are asked to take Promarker D. Thoughts?
Just wondering if it is in big pharmas best interest to know...
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.020(1.91%) |
Mkt cap ! $139.4M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.08 | $1.05 | $19.22K | 18.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9523 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 443 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.05 |
Change
0.020 ( 0.96 %) |
||||
| Open | High | Low | Volume | ||
| $1.06 | $1.07 | $1.05 | 4343 | ||
| Last updated 15.48pm 02/05/2024 ? | |||||
| PIQ (ASX) Chart |